CLOs on the Move

Hu-Friedy

www.hu-friedy.com

 
Founded in 1908, Hu-Friedy has since become a world leader in dental instrument manufacturing. Today, we take a broader view of the value we offer our customers. We are focused on delivering the highest quality product, service, and community experience in the dental industry in order to help dental professionals perform at their best. Our 10,000 dental instruments and product solutions are sold in over 100 countries, and we have more than 600 employees representing and growing our brand around the world. Headquartered in Chicago, we have offices and distribution centers in the Netherlands, Italy, Germany, China, and Japan, and ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Vitamin Discount Center

Vitamin Discount Center Incorporated is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kirby Lester Inc.

Kirby Lester Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Lake Forest, IL. To find more information about Kirby Lester Inc., please visit www.kirbylester.com

The Physicians Eye Care Center of America

The Physicians Eye Care Center of America is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healogics

Headquartered in Jacksonville, FL, Healogics is the nation`s largest provider of advanced wound care services. Healogics and its affiliated companies manage a network of Wound Care Centers® through-out the United States and the United Kingdom. Healogics technology-enabled wound care model supports the critical connection between patients with chronic wounds and multi-disciplinary teams for continuous, collaborative, patient-centered care.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.